Discontinuation of tyrosine kinase inhibitor treatment in patients who have obtained complete molecular response after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia

Discontinuation of tyrosine kinase inhibitor treatment in patients who have obtained complete molecular response after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia - Discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004798

Enrollment

Registered

2011-01-05

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukemia

Interventions

Discontinuation of tyrosine kinase inhibitor treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) No history of AP/BC while under treatment with TKI 2) Sustained complete molecular response for over 2 years 3) Has given written informed consent 4) Is able to visit the hospital at a pre required time point

Exclusion criteria

Exclusion criteria: 1) Has a history of AP/BC during TKI treatment 2) Cannot give written informed consent 3) Any patient whom the treating physician feels inappropriate for accrual

Design outcomes

Primary

Measure	Time frame
Relapse of chronic myeloid leukemia after discontinuation of tyrosine kinase inihibitors	—

Secondary

Measure	Time frame
Change in QOL status, reduction of adverse events related to tyrosine kinase inhibitor treatment, reduction of economic burden	—

Countries

Japan

Contacts

Public ContactEri Matsuki

Keio University School of Medicine Division of Hematology

erie@kk.iij4u.or.jp03-5363-3785

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026